TB
Therapeutic Areas
MeMed Pipeline
| Drug | Indication | Phase |
|---|---|---|
| MeMed BV | Bacterial vs Viral Infection Differentiation | Commercial |
| MeMed Severity | Risk Stratification for Acute Infection Deterioration | CE‑marked / FDA‑clearance pending |
| MeMed Key | Platform for Multiplex Protein Measurement | Commercial |
Leadership Team at MeMed
EE
Eran Eden, PhD
Co‑founder & CEO
BH
Barak Hershkovitz, MD
Chief Technology Officer
AR
Ariel Rubashkin
Chief Financial Officer
TG
Tanya Gottlieb, MBA, PhD
Vice President, Scientific Affairs
DA
Dalia Argaman
Vice President, Regulatory Affairs & Quality Assurance
HR
Haim Regev
Vice President, International
OH
Ori Hadomi
Chairman of the Board